The JAK-STAT Pathway Is Critical in Ventilator-Induced Diaphragm Dysfunction
- 27 Downloads
Mechanical ventilation (MV) is one of the lynchpins of modern intensive-care medicine and is life saving in many critically ill patients. Continuous ventilator support, however, results in ventilation-induced diaphragm dysfunction (VIDD) that likely prolongs patients’ need for MV and thereby leads to major associated complications and avoidable intensive care unit (ICU) deaths. Oxidative stress is a key pathogenic event in the development of VIDD, but its regulation remains largely undefined. We report here that the JAK-STAT pathway is activated in MV in the human diaphragm, as evidenced by significantly increased phosphorylation of JAK and STAT. Blockage of the JAK-STAT pathway by a JAK inhibitor in a rat MV model prevents diaphragm muscle contractile dysfunction (by ̃85%, p < 0.01). We further demonstrate that activated STAT3 compromises mitochondrial function and induces oxidative stress in vivo, and, interestingly, that oxidative stress also activates JAK-STAT. Inhibition of JAK-STAT prevents oxidative stress-induced protein oxidation and polyubiquitination and recovers mitochondrial function in cultured muscle cells. Therefore, in ventilated diaphragm muscle, activation of JAK-STAT is critical in regulating oxidative stress and is thereby central to the downstream pathogenesis of clinical VIDD. These findings establish the molecular basis for the therapeutic promise of JAK-STAT inhibitors in ventilated ICU patients.
Mechanical ventilation (MV) is an important component of modern medical practice which allows support of breathing in the intensive care unit (ICU) and during surgery requiring general anesthesia. Many patients, however, fail initial weaning from the ventilator and enter the difficult realm of prolonged ventilation. Patients who develop this ventilator dependence, though a diverse group, share the common underlying problem of substantial dysfunction of the major inspiratory muscle, the diaphragm (1, 2, 3, 4, 5, 6, 7, 8). The development of ventilator-induced diaphragm dysfunction (VIDD) appears to be a major underlying cause of prolonged ventilator-dependence with its attendant dramatic increase in morbidity and mortality (9, 10, 11, 12, 13, 14).
The pathogenesis of VIDD includes both atrophy of diaphragmatic myofibers and loss of diaphragmatic contractile function (that is, specific force) unrelated to atrophy (15, 16, 17). In previous studies, MV with diaphragm inactivity has been shown to elicit significant dysfunction and/or atrophy of myofibers in the diaphragm of humans (18, 19, 20, 21), rats (22), mice (23, 24, 25), rabbits (26) and piglets (27). With regard to the atrophy, several proteolytic events, such as activation of the ubiquitin proteasome system (UPS) (28, 29, 30), autophagy (24,25,31) and apoptosis (32, 33, 34, 35), and upregulation of calpain (36), have been demonstrated in MV models. We and others have reported that oxidative stress is induced in MV diaphragm (35,37,38) and that the elevated mitochondrial oxidative stress (MOS) in MV human diaphragm appears to be a key upstream inducer of these proteolytic events (35).
In addition to promoting protein turnover, MOS could impact specific force as well in at least two ways. MOS generates free radicals that may directly oxidize muscle proteins, altering their structure and function, including changes to myofilament structure, cross-bridge kinetics and/or a reduction of the calcium sensitivity of myofilaments (39, 40, 41, 42). Secondly, MOS is able to induce a metabolic switch, a reduction in mitochondrial oxidative phosphorylation and an increase in glycolysis (43, 44, 45, 46), which may lead to reduced overall energy supply to the muscle. Since reduction of specific force occurs prior to the presence of muscle atrophy in the ventilated human diaphragm (20,23), this component of VIDD may account for the earliest and perhaps most critical phase of the process. Therefore, understanding the basis of MOS generation in the MV diaphragm would be likely to identify targets that could be used to impact the most clinically important phase of VIDD.
The JAK-STAT pathway, consisting of Janus kinase (JAK) and signal transducer and activator of transactivation (STAT), is a signaling cascade that can be activated by cytokines, hormones and growth factors via ligand-receptor interactions. The consequentially activated JAK kinase can further phosphorylate STAT proteins, and the latter usually form dimers, translocate to the nucleus and transcriptionally activate genes. In a previous study, we found that STAT3 gene expression level was upregulated in ventilated human diaphragm and that this upregulation was linked to the activation of mitochondrial apoptosis (35). It also was recently reported that overexpression of STAT3 can lead to skeletal muscle atrophy (47). In addition, oxidative stress has been shown to activate the JAK-STAT pathway in vitro (48). Therefore, it is reasonable to speculate that MV-induced oxidative stress elevates STAT3 and thereby contributes to the muscle atrophy component of VIDD. However, whether and how the JAK-STAT pathway contributes to the reduction in diaphragm muscle specific force associated with prolonged MV remains unknown.
In the current study, we report that JAK and STAT are significantly phosphorylated/activated in both human and rat diaphragms subjected to MV. Blockade of the JAK-STAT pathway in ventilated rats dramatically prevents the loss of contractile function in their diaphragms. Overactivation of JAK-STAT induces oxidative stress in skeletal muscle in vivo, with increased protein oxidation and reduction in mitochondrial membrane potential. Interestingly, JAK-STAT also can be activated by oxidative stress, and inhibition of JAK or STAT can suppress H2O2-induced oxidative stress. Together, these findings strongly suggest that the regulation of oxidative stress via activation of JAK-STAT is crucial in the development of VIDD. This work renders the JAK-STAT pathway an optimal target for a drug to prevent VIDD.
Materials and Methods
The human samples were collected as described in detail previously at the University of Pennsylvania, Philadelphia, USA (30) and the Royal Victoria Hospital, Montreal, Quebec, Canada (31). Control diaphragm muscle biopsies were taken from patients 69.4 ± 4.7 years old (range 63 to 83 years old) with body mass index (BMI) 24.1 ± 0.52 kg/m2 (range 23.3 to 26.6 kg/m2). The ventilation time for the controls was 1.21 ± 0.1 h (range 1 to 1.5 h). The MV diaphragm samples were taken from patients 58.2 ± 4.6 years old (range 41 to 75 years), mean BMI 27.1 ± 1.77 kg/m2 (range 23 to 31 kg/m2). The average MV time for these patients was 49 ± 8.6 h (range 12 to 74 h). Nonrespiratory control muscles from these control and MV patients were taken from the quadriceps muscle, as described previously (31,35).
Mechanical Ventilation of Rats and Measurement of Diaphragm Contractile Function
Animal protocols were approved by the Institutional Animal Care and Use Committees of Rigel Pharmaceuticals, Inc. All animal experiments were carried out according to recommendations in Guide for the Care and Use of Laboratory Animals (eighth edition) (49). All surgical procedures were performed using aseptic techniques. Animals (Sprague Dawley rats, 270 ± 10g) were anesthetized to a surgical plane of anesthesia with isoflurane (2% to 4%) and a tracheotomy was performed. Rats were maintained on MV with isoflurane for 18 h using a volume-driven small-animal ventilator (CWE, Ardmore, PA, USA). Tidal volume was set at 0.7 mL/100 g body weight, respiratory rate was 80/minute. A carotid artery catheter was utilized to monitor blood pressure and to collect arterial blood samples. JAK inhibitor or control vehicle were delivered continuously through a jugular vein cannula. Heart rate was monitored throughout the study using ECG needle electrodes, and body temperature was maintained at 37°C by a rectal temperature probe connected to a Homeothermic Blanket System. Body fluid homeostasis was maintained via subcutaneous administration of 1.7 mL/kg body weight/2.5 h saline. To reduce airway secretions, glycopyrrolate (0.04 mg/kg) was administered subcutaneously every 2.5 h. After 18 h continuous MV, the rats were euthanized and diaphragms were collected and either used immediately for contractile function studies or snap frozen in liquid nitrogen for biochemical assays stored at −80°C.
Diaphragm contractile function was determined using diaphragm strips maintained ex vivo, as described previously (38). Briefly, upon completion of the study, the entire diaphragm was removed and transferred to a dissecting dish containing Krebs-Hensleit physiological solution aerated with 95% O2 to 5% CO2 gas. A muscle strip was dissected from the midcostal region of the diaphragm, which included a portion of the central tendon and ribcage. The strip was mounted vertically using serrated jaw tissue clamps, with one end fixed to an isometric force transducer on a tissue organ bath system 750 (DMT, Ann Arbor, MI, USA), and immersed in the same solution. After a 15-min equilibration, diaphragm strips were stimulated with a S88X Pulse Stimulator (Grass Technologies, Warwick, RI, USA), and platinum wire electrodes (Radnotti, Monrovia, CA, USA). Contractile measurements were taken at the optimal muscle length (Lo), the length at which maximal force is obtained. Lo was determined by stimulating the muscle at a supramaximal voltage, and systematically adjusting the muscle length. The force-frequency relationship was assessed by stimulating each strip supramaximally with 8-V pulses, with a train duration of 500 ms, at 15–160 Hz. Contractions were separated by a two-minute recovery period. Diaphragm force production was normalized as specific force based on muscle cross-sectional area (CSA). Total muscle CSA at right angles to the long axis was determined by the following calculation: total muscle CSA (mm2) = [muscle mass/(fiber length × 1.056)], where 1.056 is the density of muscle (in g/cm3). Fiber length was expressed in centimeters measured at Lo.
Reagents and Plasmids
A pan-JAK inhibitor 1 (JAK I) and STAT3 inhibitor (stattic) were purchased from EMD Millipore (Billerica, MA, USA). The JAK inhibitors, R545 and R548, were generated at Rigel Pharmaceuticals. Both are potent JAK inhibitors, with an inhibitory effect over JAK1/3 at 0.03 nmol/L and JAK2 at 1.1 nmol/L (Supplementary Table S1). H2O2 was purchased from Sigma-Aldrich (St. Louis, MO, USA). Lipofectamine 2000 was purchased from Invitrogen/Life Technologies/Thermo Fisher Scientific (Waltham, MA, USA). pcDNA3.1-STAT3C was constructed in lab by digestion of an EF1-STAT3C-ubc-GFP construct (Addgene Inc., Cambridge, MA, USA) with Hind3 and then ligated into pcDNA3.1 vector at the Hind3 site. The final construct was sequenced for validation. Prk5-JAK2V617F was a gift from Lawrence Argestinger (University of Michigan) with the permission of James Ihle (Saint Jude Children’s Research Hospital). pcs2-GFP and pcs2-bGal plasmids were from David Turner and Daniel Goldman (University of Michigan).
Cell Culture and Transfection
Plasmids were transfected into HEK293 cells with lipofectamine 2000. Three days later, ATP content or luciferase assays were performed. The cotransfected pcs2-β-Gal was used for normalization via β-Gal assay according to standard procedures.
Gene electroporation was performed as described previously (44). Briefly, 20 µg of control plasmid (pcDNA3 vector) or 20 of pcDNA3-STAT3C plasmid was mixed with 2 µg pcs2-GFP plasmid, respectively, and injected into mouse tibialis anterior (TA) muscles, immediately followed by 8 pulses of electrical shocks at 140V/cm of 60-ms duration with an interval of 100 ms, delivered by ECM830 (Harvard Apparatus, Holliston, MA, USA) square wave electroporation system. After 10 d, the TA muscles were collected, and GFP+ fibers (∼25% of the muscle) were isolated with fine forceps under the fluorescent dissecting scope. The high ratio (10 to 1) of the plasmids containing the gene of interest to the plasmid containing the GFP reporter ensures that nearly all GFP+ fibers express the gene of interest. Total protein was extracted from these GFP+ fibers by RIPA buffer and then subjected to Western blot analysis.
JC1 Mitochondrial Membrane Potential Assay
Mitochondrial membrane potential assay was performed with the JC-1 reagent (Cayman Chemical Company, Ann Arbor, MI, USA). The JC-1 reagent was diluted 1:10 in JC-1 assay buffer to prepare the JC-1 staining solution. Ten microliter of staining solution was added to the 100 µL of culture media, incubating at 37°C for 30 min. The plate was centrifuged (400g, 5 min) at room temperature, and the supernatant was removed. After being washed three times with an assay buffer, cells were then analyzed with a SpectraMax M2e Multi-Mode Microplate Reader (Molecular Devices LLC, Sunnyvale, CA, USA) for live cells (excitation/emission at 560/595 nm) and dead cells (excitation/emission at 485/535 nm).
ATP Content Measurement
ATP content in cells was measured with a Biovision ATP assay kit according to the supplier’s instructions. Briefly, cells were lysed in 200 µL ATP assay buffer provided by the manufacturer (BioVision, San Diego, CA, USA). The samples were then centrifuged at 20,183g for 15 min at 4° to pellet insoluble materials. Supernatants were collected into a fresh set of tubes for the assay. Fifty microliter of the reaction mix was added to 50 µL of lysate to start the ATP reaction. The optical density (OD) 570 nm was measured at 10 to 20 min intervals and the concentrations were calculated using the standards provided by the manufacturer. The ATP concentrations were then normalized to total protein concentrations.
Immunostaining and Western Blotting
Cultured C2C12 muscle cells on slides were fixed with 2% PFA for 30 min, and the immunostaining was performed by standard procedures. Anti-STAT3 antibody was purchased from Cell Signaling Technology (Danvers, MA, USA); and Alexa555-conjugated anti-rabbit secondary antibody and Alexa488-WGA were purchased from Invitrogen/Life Technologies/Thermo Fisher Scientific. Mounted cells were then imaged by confocal microscopy (Zeiss, Jena, Germany).
Protein expression levels were detected by Western blot analysis following standard procedures. Primary antibodies, anti-DNP (dinitrophenol) and 4-HNE (4-hydroxy-2-nonenal), were purchased from Abcam (Cambridge, England); primary antibody anti-nitrotyrosine was purchased from EMD Millipore. The rest of the antibodies used in this study were purchased from Cell Signaling Technology. The phosphorylation sites specifically recognized by these antibodies are pJAK1-tyr1022/1023, pJAK2-tyr1007/1008, pJAK3-tyr980/981, pSTAT5-tyr694 and pSTAT3-tyr705.
Gene Profiling, Quantitative PCR
Gene profiling was performed as described (35). mRNA expression levels were detected by real-time PCR by standard procedures. The primers used are listed in Supplementary Table S2.
Quantitation of gray density was performed with ImageJ software (National Institutes of Health, Bethesda, MD, USA; https://doi.org/imagej.nih.gov/ij). One-way analysis of variance (ANOVA) was used to determine the significant changes when there were more than three groups for comparison, followed by Tukey post hoc test. Student t test was used to evaluate the significance while comparing two groups in this study. A level of p < 0.05, indicated by and asterisk (*) in figures, was considered significant.
The JAK-STAT Signaling Pathway Is Activated in MV Human Diaphragm
Since the increased expression of IL6 and IL24 can lead to activation of the JAK-STAT signaling pathway by inducing the phosphorylation of JAK and STAT proteins, we examined the phosphorylation levels of JAK and STAT. We find that the phosphorylated forms of JAK1 (pJAK1-Y1022/1023), JAK2 (pJAK2-Y1007), JAK3 (pJAK3-Y980/981), STAT3 (pSTAT3-Y705) and STAT5 (pSTAT5-Y694) all are significantly upregulated in human ventilated diaphragm (Figure 1D), ranging from two-fold to 3.5-fold. Since phosphorylated STAT3 forms dimers and translocates into nuclei to regulate gene expression, we examined the subcellular distribution of STAT3 in MV diaphragm by immunostaining. These results indicate that STAT3 protein is indeed enriched in diaphragmatic myonuclei following MV (Figure 1E).
The activation of STAT appears to be diaphragm-specific, since it is not activated in the quadriceps muscles of the ventilated patients (Figure 1F). This indicates that the activation of STAT3 in diaphragm muscle is unlikely to be occurring through systemic factors.
Blockade of the JAK-STAT Pathway with a JAK Inhibitor Substantially Prevents Diaphragm Muscle Contractile Dysfunction in a Rat MV Model
Although diaphragm muscle fiber size is in fact reduced in this model of MV rat diaphragm (51), the specific force (that is, the maximum contractile force normalized to fiber size measured with stimulated diaphragm strips), is even more dramatically reduced (down to ∼50% of control). Diaphragm strips also appear somewhat more fatigable following MV, although the major difference between control and MV diaphragm strips is clearly the difference in specific force, which remains significant up to the 4-min point during a fatiguing protocol. JAK inhibitor treatment prevents the loss of maximal diaphragm force-generating capacity (median rescue of ∼85% relative to untreated MV rat diaphragm at 100 Hz; p = 0.0028) (Figures 2B–D).
These data indicate that activation of JAK-STAT is necessary for the reduction in specific force, and thereby the development of VIDD.
Enhanced Activity of JAK-STAT Induces Oxidative Stress In Vitro and In Vivo
Although the above data indicate that JAK-STAT might be critical in the development of VIDD, it remains unclear from this data which pathogenic changes this signaling pathway support that lead to VIDD. Since oxidative stress is known to be activated in both rat and human MV diaphragm (35,37,38) and is a key pathological event in directing the evolution of VIDD (35), we hypothesized that activated JAK-STAT may reduce the specific force in diaphragm muscle by inducing oxidative stress in this disease process.
Since constitutively active STAT3 increases the expression of Bcl2l11 (Bim) protein, which can alter mitochondrial membrane potential, activated JAK-STAT may affect mitochondrial function. In fact, it has been reported that overexpression of STAT3C reduces mitochondrial membrane potential (52). Here we demonstrate that overexpression of a constitutively active JAK2 reduces mitochondrial membrane potential, shown by the reduced JC1 index with overexpression (Figure 3E).
We also examined the transcriptional regulation of gene expression by STAT3 in cultured cells. Overexpression of STAT3C leads to induction of SOCS3 and Bcl2l11 (Bim) (Figure 3F). Concomitantly, UCP2, a mitochondrial transporter protein that creates a proton leak across the inner mitochondrial membrane, thereby reducing the efficiency of energy production by uncoupling oxidative phosphorylation from ATP synthesis, is induced by STAT3C (see Figure 3F). On the other hand, Cox5b, a nuclear-encoded mitochondrial gene that functions in electron transport, is significantly downregulated by STAT3C (see Figure 3F). This profile of gene expression is thus consistent with the functional decline in mitochondria induced by activated STAT3.
Consistent with the STAT3-induced changes in gene expression, MV leads to suppression of the mRNA expression of NDUFS3 and UQCRC2 in rat diaphragm muscle, and the pan-JAK inhibitor rescues the suppression of NDUFS3 (Supplementary Figure S1). This clearly indicates a role of JAK-STAT in regulating the expression of these genes that are relevant to mitochondrial function.
JAK-STAT Is Both Activated by H2O2-Induced Oxidative Stress and Is Essential for the Evolution of Oxidative Stress
These data demonstrate that H2O2-induced oxidative stress activates the JAK-STAT signaling pathway, and, conversely, that the JAK-STAT pathway is important in the development of H2O2-induced oxidative stress. These observations suggest that activation of JAK-STAT by ROS might facilitate the development of a vicious cycle during MV.
Prolonged dependence upon MV is an enormous problem in our hospitals’ intensive care units. As the duration of MV rises, so does the incidence of complications such as ventilator-associated pneumonia (53). The longer the period of full ventilator support, the more severe VIDD becomes (20), creating a downward spiral that may become irreversible and even result in death. An enormous cost in both lives and health system dollars is thus incurred by the problem of VIDD. Prevention of VIDD would be likely to have a major impact upon the morbidity, mortality and costs of intensive care medicine.
In addition to being the first demonstration of the activation of JAK-STAT in MV human diaphragm tissue, the current study goes beyond a previous publication concerning the JAK-STAT pathway in VIDD (51) by elucidating the underlying mechanism by which JAK-STAT increases oxidative stress. We observe that the altered expression of STAT3-regulated genes, such as Bim, UCP and Cox5a, impacts mitochondrial function via reducing membrane potential and/or reducing the efficiency of ATP generation. We also show that the expression of NDUFS3, a gene that encodes a core subunit of the mitochondrial membrane respiratory chain (complex I), is suppressed by MV but recovered with JAK inhibitor treatment. This transcriptional regulation is consistent with the fact that the nuclear localization of the transcriptional factor STAT3 increases following phosphorylation at tyrosine 705 (STAT3-Y705) (48). In addition to the effect via STAT-regulated genes, STAT3 may also directly alter mitochondrial function by associating with components of the mitochondrial respiratory chain. This effect is regulated by another phosphorylation site on STAT3, the serine 727 (51,54,55).
Oxidative stress may reduce the specific force of skeletal muscle in several ways, which have been previously reviewed (39, 40, 41, 42), including alteration of myofilament structure, cross-bridge kinetics, calcium sensitivity and energy supply. Activated STAT3 has been suggested to regulate energy metabolism by suppressing mitochondrial function in cancer cells (52). In the current study, we observe that STAT3 induces protein oxidation and disables mitochondrial function in muscle cells. It is thus possible that JAK-STAT affects the specific force of diaphragm muscle by both posttranslational modification (for example, ubiquitination, oxidation and nitration) of proteins, as well as by compromising the energy supply. Since protein modifications can occur rapidly and directly affect muscle contractile function, they might account for the rapid occurrence of diaphragm weakness after the institution of MV. The upstream signaling pathways that regulate oxidative stress in muscle cells may thus affect muscle contractility, and herein we provide the detailed evidence that JAK-STAT is an important one of these upstream pathways.
Beyond the functional role of STAT3 in reducing the specific force of diaphragm muscle in MV, our findings also directly link STAT3 activation to atrophy of the muscle fibers via increases in protein ubiquitination. Ventilation-induced diaphragm muscle atrophy is partially blocked by JAK inhibition (51), implying that JAK-STAT also contributes to VIDD via regulation of muscle mass. In addition to the 20S proteasome-mediated degradation of oxidized proteins, STAT3-induced muscle atrophy, like FoxO-induced protein degradation, occurs also through activation of the ATP-dependent 26S ubiquitin-proteasome system (UPS). This observation adds another signaling pathway upstream of muscle atrophy that is additive to the previously reported FoxO-induced protein degradation in VIDD, both of which act through the activation of UPS. JAK-STAT activation, then, plays a central role underlying both of the two changes that constitute the pathogenesis of VIDD, atrophy and intrinsic dysfunction.
Although JAK-STAT is shown here to activate oxidative stress, we also report that oxidative stress is able to activate JAK-STAT in muscle cells in vitro. The creation of this apparent vicious cycle suggests that activation of JAK-STAT is likely to be a critical step in the development of oxidative stress in ventilated diaphragm muscle, perhaps underlying the surprisingly rapid evolution of VIDD as compared with, for example, disuse weakness of limb muscle. It is possible that the activation of JAK-STAT by oxidative stress occurs via cytokines, such as interleukins and VEGF, as these factors are induced by H2O2 in cultured muscle cells and in ventilated diaphragm (Figure 1, Supplementary Figure S3). It is not surprising that some cytokines/factors are upregulated in diaphragm by mechanical ventilation (24),51; also see Figures 1A–C). What remains to be elucidated is how these secretory cytokines/factors could function locally within diaphragm tissue subjected to MV without causing systemic (for example, nonrespiratory muscle) atrophy. It will be worth exploring whether blocking or neutralizing these cytokines with competitive compounds or antibodies would ameliorate VIDD.
Finally, we have demonstrated the effectiveness of a JAK inhibitor, R545, in preventing MV-induced diaphragm weakness, which indicates the critical role of the JAK-STAT pathway in the development of VIDD. R545 is a nominally selective JAK1/3 inhibitor based on an in vitro cell-based assay, but it retains a potent inhibitory effect on JAK2 (Supplementary Table S1). When the compound is delivered into a rat by continuous infusion at the doses used, it would be very difficult to assert that it only inhibits JAK1/3. In our in vitro oxidative stress model, R545 and the pan-JAK inhibitor I (JAK I) appear to work equally well. It remains to be elucidated in vivo whether or not a pan-JAK inhibitor will achieve even better recovery of diaphragm muscle dysfunction than the nominally selective JAK 1/3 inhibitors. It would be also interesting in the future to test even more specific JAK inhibitors to investigate their effect.
Our in vivo demonstration of the prevention of ventilator-associated diaphragm weakness by JAK inhibition, based upon the described solid understanding of the molecular mechanisms of VIDD, provides strong support for continued development of JAK-STATtargeted drugs to prevent VIDD in the clinic. Since the reduction in the specific contractile force of the diaphragm occurs at the earliest stage of VIDD, prior to the onset of diaphragm muscle atrophy, it is possible that JAK-STAT inhibitors would have particular value by impacting the first, most clinically important component of the clinical syndrome.
We have established that the JAK-STAT signaling pathway is activated in the diaphragm of rats and humans subjected to mechanical ventilation. This posttranslational activation of JAK-STAT leads to a reduction of diaphragm contractility through, at least in part, the induction of mitochondrial oxidative stress. JAK-STAT activation appears to be critical in regulating this oxidative stress and is thereby central to the downstream pathogenesis of clinical VIDD. This finding establishes the molecular basis for the therapeutic promise of JAK-STAT inhibitors in ventilated ICU patients, and it identifies a clear mechanism of action that would favor taking such a drug to clinical trials.
IJ Smith, GL Godinez, BK Singh, DG Payan, and TM Kinsella are employees and/or stockholders of Rigel Pharmaceuticals, Inc.
We are grateful to Lawrence Argetsinger (University of Michigan) for providing JAK2 plasmids for this study. We also thank Bianca Kapoor and Isaac Ghansah, and Kun Wang and Yang Gao (Stanford University); and Kelly M McCaughey and Raniel R Alcantara (Rigel Pharmaceuticals) for technical assistance. This work is supported by a Veterans Administration (VA) Biomedical Laboratory R&D Merit Review grant to JB Shrager, and by the grants from the NIH (TR01 AG047820 and R37 AG023806) and the VA (Biomedical Laboratory R&D and Rehab R&D) Merit Reviews to TA Rando.
- 49.Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council of the National Academies. (2011) Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press.Google Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)